Overcoming Glioblastoma Resistance
Glioblastoma multiforme is one of the most aggressive forms of brain cancer and is unfortunately associated with a poor prognosis. Despite intensive approaches combining surgery, radiotherapy, and chemotherapy, the disease recurs in most cases. This ability to evade treatments and develop resistance represents a major challenge and underscores the urgent need for innovative therapeutic strategies for patients.
Outsmarting Cancer Resistance
Sachin Katyal, a researcher at the University of Manitoba and the Paul Albrechtsen Research Institute CancerCare Manitoba, is studying why certain brain tumors become less sensitive to chemotherapy and ultimately recur. His project focuses on a protein called XRCC1, which is involved in DNA repair and may play a key role in this resistance.
With support from the Cancer Research Society (CRS), his team is first exploring the potential of XRCC1 as a biomarker, with the goal of identifying tumors that are most likely to resist treatment and thereby guiding more precise therapeutic decisions.
The project then aims to test drugs already used in clinical practice, as well as a novel molecule developed in the laboratory, that can inhibit XRCC1 activity, in order to determine whether tumors can be re-sensitized to chemotherapy. Ultimately, this approach could enable treatments to be tailored to the molecular profiles of tumors and improve their effectiveness in patients with glioblastoma.
Your donations make science happen. New advancements and findings are happening every day but these funds allow us to test new theories, advance drug studies and continue our efforts to cure, detect or prevent cancer or, at least, improve the lives of people and their families, stricken with cancer. Research costs money and your dollars are instrumental to keep our research studies going.
Your impact
Research advances every day thanks to you. Your support helps transform promising projects into concrete solutions. It contributes to a better understanding of cancer and its underlying mechanisms. Ultimately, these advances make it possible to deliver more effective, personalized care for patients while improving their quality of life.
Project Title: XRCC1 is a novel biomarker and therapeutic target to counteract treatment-resistant Glioblastoma multiforme
Manitoba
2024-2026,
$130,000